A new method of quantitatively assessing the opening of the blood-brain barrier in murine animal models

Journal of Neuroscience Methods

Volumn 207, Issue 2, 2012, Pages 125-129

  Blanchette, Marie ^a   Michaud, Karine ^b   Fortin, David ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

Albumin indirect immunohistochemistry; Blood brain barrier; Blood brain barrier disruption; Quantitative evaluation

Indexed keywords

ALBUMIN; EVANS BLUE; MANNITOL;

ALBUMIN INDIRECT IMMUNOHISTOCHEMISTRY; ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BLOOD BRAIN BARRIER DISRUPTION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG ADMINISTRATION; DRUG BIOAVAILABILITY; DRUG PENETRATION; HYPEROSMOLARITY; IMAGE ANALYSIS; MALE; MEMBRANE PERMEABILITY; NONHUMAN; OSMOTIC PRESSURE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT;

ANIMALS; BLOOD-BRAIN BARRIER; DIURETICS, OSMOTIC; EVANS BLUE; INFUSION PUMPS; MALE; MANNITOL; MODELS, ANIMAL; RANDOM ALLOCATION; RATS; RATS, INBRED F344;

EID: 84860342240     PISSN: 01650270     EISSN: 1872678X     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2012.03.012     Document Type: Article

References (26)

1. Blanchette M., Pellerin M., Tremblay L., Lepage M., Fortin D. Real-time monitoring of gadolinium diethylenetriamine penta-acetic acid during osmotic blood-brain barrier disruption using magnetic resonance imaging in normal wistar rats. Neurosurgery 2009, 65:344-350. [discussion 50-1].
2. Bhattacharjee A.K., Nagashima T., Kondoh T., Tamaki N. Quantification of early blood-brain barrier disruption by in situ brain perfusion technique. Brain Res Prot 2001, 8:126-131.
3. Boyle F.M., Eller S.L., Grossman S.A. Penetration of intra-arterially administered vincristine in experimental brain tumor. Neuro Oncol 2004, 6:300-305.
4. Bradford R., Koppel H., Pilkington G.J., Thomas D.G., Darling J.L. Heterogeneity of chemosensitivity in six clonal cell lines derived from a spontaneous murine astrocytoma and its relationship to genotypic and phenotypic characteristics. J Neurooncol 1997, 34:247-261.
5. Fortin D. Altering the properties of the blood-brain barrier: disruption and permeabilization. Prog Drug Res 2003, 61:125-154.
6. Fortin D. The blood-brain barrier should not be underestimated in neuro-oncology. Rev Neurol (Paris) 2004, 160:523-532.
7. Fortin D., Adams R., Gallez A. A blood-brain barrier disruption model eliminating the hemodynamic effect of ketamine. Can J Neurol Sci 2004, 31:248-253.
8. Fortin D., Desjardins A., Benko A., Niyonsega T., Boudrias M. Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience. Cancer 2005, 103:2606-2615.
9. Fortin D., Gendron C., Boudrias M., Garant M.P. Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in the treatment of cerebral metastasis. Cancer 2007, 109:751-760.
10. Fortin D., McCormick C.I., Remsen L.G., Nixon R., Neuwelt E.A. Unexpected neurotoxicity of etoposide phosphate administered in combination with other chemotherapeutic agents after blood-brain barrier modification to enhance delivery, using propofol for general anesthesia, in a rat model. Neurosurgery 2000, 47:199-207.
11. Fortin D., Neuwelt E.A. Therapeutic manipulation of the blood-brain barrier. Neurobase-neurosurgery. Medlink CD-ROM 2003.
12. Kraemer D.F., Fortin D., Doolittle N.D., Neuwelt E.A. Association of total dose intensity of chemotherapy in primary central nervous system lymphoma (human non-acquired immunodeficiency syndrome) and survival. Neurosurgery 2001, 48:1033-1040. [discussion 40-1].
13. Kraemer D.F., Fortin D., Neuwelt E.A. Chemotherapeutic dose intensification for treatment of malignant brain tumors: recent developments and future directions. Curr Neurol Neurosci Rep 2002, 2:216-224.
14. Kroll R.A., Neuwelt E.A. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery 1998, 42:1083-1099. [discussion 99-100].
15. Kroll R.A., Pagel M.A., Muldoon L.L., Roman-Goldstein S., Neuwelt E.A. Increasing volume of distribution to the brain with interstitial infusion: dose, rather than convection, might be the most important factor. Neurosurgery 1996, 38:746-752. [discussion 52-54].
16. Neuwelt E., Abbott N.J., Abrey L., Banks W.A., Blakley B., Davis T., et al. Strategies to advance translational research into brain barriers. Lancet Neurol 2008, 7:84-96.
17. Neuwelt E.A. Implications of the blood-brain barrier and its manipulation 1989, New York, Plenum Press.
18. Neuwelt E.A. Reversible osmotic blood-brain barrier disruption in humans: implications for the chemotherapy of malignant brain tumors. Neurosurgery 1980, 7:204.
19. Neuwelt E.A., Howieson J., Frenkel E.P., Specht H.D., Weigel R., Buchan C.G., et al. Therapeutic efficacy of multiagent chemotherapy with drug delivery enhancement by blood-brain barrier modification in glioblastoma. Neurosurgery 1986, 19:573-582.
20. Neuwelt E.A., Maravilla K.R., Frenkel E.P., Barnett P., Hill S., Moore R.J. Use of enhanced computerized tomography to evaluate osmotic blood-brain barrier disruption. Neurosurgery 1980, 6:49-56.
21. Pardridge W.M. Drug delivery to the brain. J Cereb Blood Flow Metab 1997, 17:713-731.
22. Pardridge W.M. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2005, 2:3-14.
23. 2, and other factors on osmotic blood-brain barrier disruption in rats with brain tumor xenografts. Anesth Analg 1999, 88:559-567.
24. Roman-Goldstein S., Clunie D.A., Stevens J., Hogan R., Monard J., Ramsey F., et al. Osmotic blood-brain barrier disruption: CT and radionuclide imaging. AJNR Am J Neuroradiol 1994, 15:581-590.
25. Swanson R.A., Morton M.T., Tsao-Wu G., Savalos R.A., Davidson C., Sharp F.R. A semiautomated method for measuring brain infarct volume. J Cereb Blood Flow Metab 1990, 10:290-293.
26. Vorbrodt A.W., Dobrogowska D.H., Tarnawski M., Lossinsky A.S. A quantitative immunocytochemical study of the osmotic opening of the blood-brain barrier to endogenous albumin. J Neurocytol 1994, 23:792-800.